H.C. Wainwright analyst Raghuram Selvaraju adjusted the firm’s price target for Timber Pharmaceuticals shares to $11 from $1 following the 1-for-50 reverse stock split that took effect in early November 2022.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TMBR:
- Timber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2022 Financial Results
- Timber announces publication of sub-analysis of Phase 2b CONTROL study
- Timber Pharmaceuticals Receives European Orphan Drug Designation for TMB-001 in X-Linked Recessive Ichthyosis
- Timber Pharmaceuticals receives European ODD for TMB-001
